Taliglucerase alfa
- Generic Name
- Taliglucerase alfa
- Brand Names
- Elelyso
- Drug Type
- Biotech
- CAS Number
- 37228-64-1
- Unique Ingredient Identifier
- N69L6LM4QU
Overview
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Background
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Indication
For the treatment of adult Type 1 Gaucher disease.
Associated Conditions
- Gaucher Disease, Type 1
- Gaucher Disease, Type III
FDA Approved Products
ELELYSO
Manufacturer:Pfizer Laboratories Div Pfizer Inc
Route:INTRAVENOUS
Strength:200 U in 5 mL
Approved: 2023/05/18
NDC:0069-0106
Singapore Approved Products
ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL
Manufacturer:Pharmacia and Upjohn Company LLC
Form:INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Strength:200Units/vial
Online:Yes
Approved: 2023/05/03
Approval:SIN16770P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath